



Avalanche Biotechnologies to Present at Upcoming Scientific Meetings

April 27, 2016

MENLO PARK, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced today that in May, it and its research partner Regeneron will present at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting in Seattle, as well as at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting in Washington, DC.

ARVO 2016 Annual Meeting

May 1-5, Seattle

**Presentation Session #266 Room 615/617
Monday, May 2, 3:45 p.m. - 5:30 p.m. PT**

Intraocular Gene Expression and Functional Safety Evaluation Following Intravitreal Delivery of Cone Specific GFP-Expressing AAV Vectors in Nonhuman Primates

Presenter: Kathryn Woodburn, PhD, Avalanche Biotechnologies, Inc.

**Poster Session # 141
Sunday, May 1, 1:30 p.m. – 3:15 p.m. PT**

Presentation # 781 Temporal Expression of Cone-Specific Recombinant Adeno-Associated Viruses in Multiple Species Exhibiting Various Cone Levels as Potential Models to Treat Cone-Associated Disorders

Presenter: Alex Bauer, Avalanche Biotechnologies, Inc.

Presentation # 782 *In Vivo* Assessment of the Impact of Neutralizing Antibodies on Intravitreal AAV2.7m8 Administration

Presenter: Annahita Keravala, PhD, Avalanche Biotechnologies, Inc.

Presentation # 786 Evaluation of AAV Variants for Transgene Expression and Distribution in Rabbit and Non-Human Primate Eyes Following Intravitreal Delivery

Presenter: Bibiana Iglesias, Regeneron Pharmaceuticals, Inc.

**Poster Session # 324
Tuesday, May 3, 8:30 a.m. - 10:15 a.m. PT**

Presentation # 3369 Anatomical and Functional Effects of Subretinal rAAV.sVEGFR-1 Gene Therapy on Retinal Choroidal Structures in Nonhuman Primates

Presenter: Kathryn Woodburn PhD, Avalanche Biotechnologies Inc.

ASGCT 2016 Annual Meeting

May 4-7, Washington, DC

Session title: Delivery Questions for Neural Applications

Room: Exhibit Hall C & B South

Friday, May 6, 6:00 p.m. – 8:00 p.m. ET

Abstract # 607 Organotypic Culture of Adult Porcine Retina as an *In Vitro* Screening Model for AAV-Mediated Gene Therapy in Ophthalmology

Presenter: Annahita Keravala, PhD, Avalanche Biotechnologies Inc.

About Avalanche Biotechnologies, Inc.

Avalanche is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients suffering from diseases with few or burdensome treatment options. Avalanche is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. With significant capabilities and expertise in vector optimization, process development and manufacturing, Avalanche seeks to discover and develop targets in ophthalmology and beyond. For more information, please visit www.avalanchebiotech.com.

CONTACT:

Investor Contact

Lauren Glaser

(650) 656-9347

lauren@avalanchebiotech.com



Avalanche Biotechnologies, Inc.